Patents by Inventor Thomas Dumortier

Thomas Dumortier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dosage regimen of an S1P receptor modulator
    Patent number: 11759436
    Abstract: The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection caused by varicella zoster virus and vaccinating the patient prior to administration of an S1P receptor modulator or agonist.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 19, 2023
    Assignee: Novartis AG
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder, William C. Collins
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20230086687
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: April 28, 2022
    Publication date: March 23, 2023
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder
  • METHODS OF TREATING AUTOIMMUNE DISEASES USING INTERLEUKIN-17 (IL-17) ANTAGONISTS
    Publication number: 20220363749
    Abstract: The present disclosure relates to methods for treating patients having autoimmune diseases, e.g., methods for treating psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), e.g., non-radiographic axial spondyloarthritis (nr-axSpA) or ankylosing spondylitis (AS), using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab. Also disclosed herein are methods for inhibiting the progression of structural damage in PsA and axSpA patients using IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab. The present disclosure also provides medicaments, pharmaceutical formulations, dosage forms, and kits for use in the disclosed methods.
    Type: Application
    Filed: September 18, 2020
    Publication date: November 17, 2022
    Inventors: Abhijit BAPAT, Thomas DUMORTIER, Meryl MENDELSON, Shephard MPOFU, Luminita PRICOP
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20220142949
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: September 20, 2021
    Publication date: May 12, 2022
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20200330407
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: May 5, 2020
    Publication date: October 22, 2020
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20200222338
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: January 10, 2020
    Publication date: July 16, 2020
    Inventors: Craig Boulton, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER, William C. COLLINS
  • Dosage regimen of an S1P receptor modulator
    Patent number: 10543179
    Abstract: The present invention relates to a dosage regimen of an S1P receptor modulator or agonist in the course of the treatment of patients suffering from an inflammatory or autoimmune disorder, for example multiple sclerosis. Specifically, the present invention relates to testing a patient for a history of infection and vaccinating the patient prior to administration of fingolimod or a pharmaceutically acceptable salt thereof at a daily dosage of 0.5 mg.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: January 28, 2020
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder, William C. Collins
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20190091180
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: November 26, 2018
    Publication date: March 28, 2019
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20180289638
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: June 11, 2018
    Publication date: October 11, 2018
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20180263929
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: Craig Boulton, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20180263930
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: May 23, 2018
    Publication date: September 20, 2018
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20170304226
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: July 11, 2017
    Publication date: October 26, 2017
    Inventors: Craig Boulton, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20170189353
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: March 21, 2017
    Publication date: July 6, 2017
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20160263061
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: May 23, 2016
    Publication date: September 15, 2016
    Applicant: Novartis AG
    Inventors: Robert Schmouder, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20160256416
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: May 12, 2016
    Publication date: September 8, 2016
    Applicant: Novartis AG
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20160081949
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: December 2, 2015
    Publication date: March 24, 2016
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20140187516
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: February 10, 2014
    Publication date: July 3, 2014
    Applicant: NOVARTIS AG
    Inventors: Craig BOULTON, Pascale BURTIN, Olivier DAVID, Ana de VERA, Thomas DUMORTIER, Irene HUNT, Robert SCHMOUDER
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20140148415
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
    Type: Application
    Filed: January 31, 2014
    Publication date: May 29, 2014
    Applicant: NOVARTIS AG
    Inventors: Robert SCHMOUDER, Thomas DUMORTIER, Olivier DAVID, Michael LOOBY
  • DOSAGE REGIMEN FOR A S1P RECEPTOR AGONIST
    Publication number: 20140066657
    Abstract: S1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage
    Type: Application
    Filed: September 6, 2013
    Publication date: March 6, 2014
    Applicant: Novartis AG
    Inventors: Robert Schmouder, Thomas Dumortier, Olivier David, Michael Looby
  • DOSAGE REGIMEN OF AN S1P RECEPTOR MODULATOR
    Publication number: 20120264719
    Abstract: S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.
    Type: Application
    Filed: September 20, 2010
    Publication date: October 18, 2012
    Inventors: Craig Boulton, Pascale Burtin, Olivier David, Ana de Vera, Thomas Dumortier, Irene Hunt, Robert Schmouder